



1P-219-T025

Monoclonal Antibody to CD29 Phycoerythrin (PE) conjugated (25 tests)

Clone:	MEM-101A
Isotype:	Mouse IgG1
Specificity:	The antibody MEM-101A reacts with CD29 (integrin beta1 chain), a 130 kDa single chain type I glycoprotein expressed as a heterodimer (non-covalently associated with the integrin alpha subunits 1-6). CD29 is broadly expressed on majority of hematopoietic and non-hematopoietic cells (leukocytes, platelets, fibroblasts, endothelial cells, epithelial cells and mast cells). HLDA VI; WS Code AS A048
Immunogen:	Raji Burkitt's lymphoma cell line
Species Reactivity:	Human, Porcine, Canine (Dog)
Negative Species:	Mouse
Preparation:	The purified antibody is conjugated with R-Phycoerythrin (PE) under optimum conditions. The conjugate is purified by size-exclusion chromatography and adjusted for direct use. No reconstitution is necessary.
Storage Buffer:	The reagent is provided in phosphate buffered saline (PBS) containing 15 mM sodium azide and 0.2% (w/v) high-grade protease free Bovine Serum Albumin (BSA) as a stabilizing agent.
Storage / Stability:	Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not use after expiration date stamped on vial label. Short-term exposure to room temperature should not affect the quality of the reagent. However, if reagent is stored under any conditions other than those specified, the conditions must be verified by the user.
Usage:	The reagent is designed for Flow Cytometry analysis of human blood cells using 20 µl reagent / 100 µl of whole blood or 10 ⁶ cells in a suspension. The content of a vial (0.5 ml) is sufficient for 25 tests.
Expiration:	See vial label
Lot Number:	See vial label
Background:	CD29 (beta1 integrin subunit, GPIIa) forms non-covalently linked heterodimers with at least 6 different alpha chains (alpha1-alpha6, CD49a-f) determining the binding properties of beta1 (VLA) integrins. These integrins mediate cell adhesion to collagen, fibronectin, laminin and other extracellular matrix (ECM) components. This interaction hinders cell death, whereas disruption of anchorage to ECM leads to apoptosis. Decreased expression of most beta1 integrins correlates with acquiring multidrug resistance of tumour cells during selection in presence of antitumour drug. In platelets, translocation of intracellular pool of beta1 integrins to the plasma membrane following thrombin stimulation. These integrins are also up-regulated in leukocytes during emigration and extravascular migration and appear to be critically involved in regulating the immune cell trafficking from blood to tissue, as well as in regulating tissue damage and disease symptoms related to inflammatory bowel disease. Through a beta1 integrin-dependent mechanism, fibronectin and type I collagen enhance cytokine secretion of human airway smooth muscle in response to IL-1beta.

For laboratory research only, not for drug, diagnostic or other use.

**Antibodies****References:**

- *Wencel-Drake JD, Dieter MG, Lam SC: Immunolocalization of beta 1 integrins in platelets and platelet-derived microvesicles. *Blood*. 1993 Aug 15;82(4):1197-203.
- *Werr J, Johansson J, Eriksson EE, Hedqvist P, Ruoslahti E, Lindbom L: Integrin alpha(2)beta(1) (VLA-2) is a principal receptor used by neutrophils for locomotion in extravascular tissue. *Blood*. 2000 Mar 1;95(5):1804-9.
- *Peng Q, Lai D, Nguyen TT, Chan V, Matsuda T, Hirst SJ: Multiple beta 1 integrins mediate enhancement of human airway smooth muscle cytokine secretion by fibronectin and type I collagen. *J Immunol*. 2005 Feb 15;174(4):2258-64.
- *Lundberg S, Lindholm J, Lindbom L, Hellström PM, Werr J: Integrin alpha2beta1 regulates neutrophil recruitment and inflammatory activity in experimental colitis in mice. *Inflamm Bowel Dis*. 2006 Mar;12(3):172-7.
- *Morozevich GE, Kozlova NI, Preobrazhenskaya ME, Ushakova NA, Eltsov IA, Shtil AA, Berman AE: The role of beta1 integrin subfamily in anchorage-dependent apoptosis of breast carcinoma cells differing in multidrug resistance. *Biochemistry (Mosc)*. 2006 May;71(5):489-95.
- *Leukocyte Typing VI., Kishimoto T. et al. (Eds.), Garland Publishing Inc. (1997).
- *Plánka L, Necas A, Srnc R, Rauser P, Starý D, Jancár J, Amler E, Filová E, Hlucilová J, Kren L, Gál P: Use of allogenic stem cells for the prevention of bone bridge formation in miniature pigs. *Physiol Res*. 2009;58(6):885-93.
- *Simova S, Klima M, Cermak L, Sourkova V, Andera L: Arf and Rho GAP adapter protein ARAP1 participates in the mobilization of TRAIL-R1/DR4 to the plasma membrane. *Apoptosis*. 2008 Mar;13(3):423-36.

For laboratory research only, not for drug, diagnostic or other use.